Diplomat Pharmacy Receives a Hold from J.P. MorganBy Ryan Adsit
According to TipRanks.com, Gill is a 4-star analyst with an average return of 9.9% and a 57.1% success rate. Gill covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, The Advisory Board, and AmerisourceBergen.
Currently, the analyst consensus on Diplomat Pharmacy is Hold and the average price target is $17.67, representing a 27.3% upside.
In a report released today, Avondale also downgraded the stock to Hold.
Based on Diplomat Pharmacy’s latest earnings report from March 31, the company posted quarterly revenue of $995.9M and quarterly net profit of $15.43M. In comparison, last year the company earned revenue of $946.9M and had a net profit of $15.96M.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. Last month, Philip Hagerman, the Chairman & CEO of DPLO bought 3,347 shares.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It focuses on improving the lives of patients with complex chronic diseases. The company offers a broad range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost specialty drugs. Diplomat Pharmacy was founded by Dale Hagerman and Phil Hagerman in 1975 and is headquartered in Flint, MI.